Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 5, 2002, Pages 651-655

  See, H T ^b   Koo, Wen Hsin ^a   Ang, P ^b   Au, E ^b   Ang, P T ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NONE

Author keywords

Chemotherapy; Diarrhoea; Irinotecan; Metastatic colorectal carcinoma

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; FLUOROURACIL; IRINOTECAN; LOPERAMIDE;

ABDOMINAL CRAMP; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; LONG TERM CARE; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; SINGAPORE; SURVIVAL TIME;

EID: 0036755981     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Chia K S, Seow A, Lee H P, Shanmugaratnam K. Cancer incidence in Singapore 1993-1997. Singapore: Singapore Cancer Registry, 2000. Report No. 5.
2. Erlichman C, Fine S, Wong A, Elhakim T. A randomised trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6:469-75.
3. Hsiang Y H, Liu L F. Identification of mammalian DNA topoisomerise 1 as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48:1722-6.
4. Cunningham D, Pyrhonen S, James R D, Punt C J, Hickish T F, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8.
5. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12.
6. Saltz L B, Cox J V, Blanke C, Rosen L S, Fehrenbacher L, Moore M J, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-14.
7. Ratain M J. Insights into the pharmacokinetics and pharmacodynamics of irinotecan [editorial]. Clin Cancer Res 2000; 6:3393-4.
8. Connell M J. A phase III trial of 5 fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 1989; 63:1026-30.
9. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takenchi M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumours. Cancer Res 1987; 47:5944-7.
10. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN 38, a metabolite of camptothecin derivative CPT-11, in the anti-tumour effect of CPT-11. Cancer Res 1991; 51:4187-91.
11. Abigerges D, Chabot G C, Armand J P, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of camptothecin analogue irinotecan administered every three weeks in cancer patients. J Clin Oncol 1995; 13:210-21.
12. Abigerges D, Armand J P, Chabot G C, Da Costa L, Fadel E, Cote C, et al. Irinotecan (CPT-11) high dose escalation using intensive high dose loperamide to control diarrhoea. J Natl Cancer Inst 1994; 86:447-9.
13. Rougier P, Bugat R, Douillard JY, Culine S, Becouarn Y, Ychou M, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naïve patients and patients pre-treated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-60.
14. Pitot H C, Wender D B, O'Connell M J, Schroeder G, Goldberg R M, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2910-9.